Skip to main content
. 2006 Apr 19;2006(2):CD005321. doi: 10.1002/14651858.CD005321.pub2

5. Clinical benefit table: Artz versus placebo. Continuous outcome measures.

Study Time Treatment Outcome N of Pts Baseline Mean End of Study Mean Absolute Benefit Relative Difference
Lohmander 1996 1‐4 wk E: Artzal Pain (0‐100 mm VAS) 96 49.76 36.64 2.48 (W) 5.2% (W)
    C: Saline   93 47.84 32.24    
Lohmander 1996 5‐13 wk E: Artzal Pain (0‐100 mm VAS) 96 49.76 34.69 ‐2.46 (I) ‐5.1% (I)
    C: Saline   93 47.84 35.23    
Lohmander 1996 14‐26 wk E: Artzal Pain (0‐100 mm VAS) 96 49.76 33.65 ‐3.67 (I) ‐7.7% (I)
    C: Saline   93 47.84 35.40    
Lohmander 1996 1‐4 wk E: Artzal Activity level (0‐100 mm VAS) 96 62.98 43.69 4.77 (W) 7.4% (W)
    C: Saline   93 64.71 40.65    
Lohmander 1996 5‐13 wk E: Artzal Activity level (0‐100 mm VAS) 96 62.98 45.17 4.71 (W) 7.3% (W)
    C: Saline   93 64.71 42.19    
Lohmander 1996 14‐26 wk E: Artzal Activity level (0‐100 mm VAS) 96 62.98 41.67 ‐0.68 (I) ‐1.1% (I)
    C: Saline   93 64.71 44.08    
Lohmander 1996 14‐26 wk E: Artzal Lequesne (0‐24) 120 9.89 7.98 ‐0.17 (I) ‐1.8% (I)
    C: Saline   120 9.56 7.82    
Lohmander 1996 1‐4 wk E: Artzal Knee function (0‐100 mm VAS) 96 53.76 38.00 2.17 (W) 4.1% (W)
    C: Saline   93 53.02 35.09    
Lohmander 1996 5‐13 wk E: Artzal Knee function (0‐100 mm VAS) 96 53.76 42.34 4.09 (W) 7.7% (W)
    C: Saline   93 53.02 37.51    
Lohmander 1996 14‐26 wk E: Artzal Knee function (0‐100 mm VAS) 96 53.76 38.27 ‐2.3 (I) ‐4.3% (I)
    C: Saline   93 53.02 39.83    
Karlsson 2002a 1‐4 wk E: Artzal Pain on weight bearing (0‐100 mm VAS) 92 64 44 1.0 (W) 1.5% (W)
    C: Saline   66 65 44    
Karlsson 2002a 5‐13 wk E: Artzal Pain on weight bearing (0‐100 mm VAS) 92 64 42 ‐3 (I) ‐4.6% (I)
    C: Saline   66 65 46    
Karlsson 2002a 14‐26 wk E: Artzal Pain on weight bearing (0‐100 mm VAS) 92 64 48 5 (W) 7.7% (W)
    C: Saline   66 65 44    
Karlsson 2002a 5‐13 wk E: Artzal WOMAC (0‐100 mm VAS) 92 48.7 34.7 4.2 (W) 8.6% (W)
    C: Saline   66 48.9 30.7    
Karlsson 2002a 14‐26 wk E: Artzal WOMAC (0‐100 mm VAS) 92 48.7 37.4 5.5 (W) 11.2% (W)
    C: Saline   66 48.9 32.1    
Karlsson 2002a 14‐26 wk E: Artzal Lequesne Index (0‐24) 92 13.9 10.0 0.8 (W) 5.9% (W)
    C: Saline   66 13.6 8.9    
Puhl 1993 1‐4 wk E: Artz Pain (0‐100 mm VAS) 95 54.10 29.14 ‐4.96 (I) ‐9.6% (I)
    C: Vehicle   100 51.40 31.40    
Puhl 1993 5‐13 wk E: Artz Pain (0‐100 mm VAS) 95 54.10 26.50 ‐10.2 (I) ‐19.8 (I)
    C: Vehicle   100 51.40 34.00    
Puhl 1993 1‐4 wk E: Artz Lequesne Index (0‐24) 95 10.4 7.19 ‐0.81 (I) ‐8.6% (I)
    C: Vehicle   100 9.4 7.00    
Puhl 1993 5‐13 wk E: Artz Lequesne Index (0‐24) 95 10.4 6.43 ‐1.36 (I) ‐14.5% (I)
    C: Vehicle   100 9.4 6.79    
Shichikawa 1983b 1‐4 wk E: Artz Pain (0‐3) 52 1.03 0.66 0.02 (W) 1.8% (W)
    C: Vehicle   55 1.12 0.73    
Shichikawa 1983b 1‐4 wk E: Artz Range of motion (flexion degrees) 52 133.4 135.65 ‐1.75 (W) ‐1.4% (W)
    C: Vehicle   55 128.6 132.60    
Day 2004 5‐13 wk E: Artz WOMAC pain (0‐20 Likert) 116 7.96 3.84 ‐0.05 (I) ‐0.6% (I)
    C: Saline   124 8.68 4.61    
Day 2004   E: Artz WOMAC function (0‐68 Likert) 116 28.07 11.41 4.06 (W) 13% (W)
    C: Saline   124 31.25 10.53    
Day 2004   E: Artz WOMAC stiffness (0‐8) 116 3.70 1.42 0.07 (W) 1.8% (W)
    C: Saline   124 3.79 1.44